Jerri Rook
Last active: 3/3/2020

Profile

None provided

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Biased M receptor-positive allosteric modulators reveal role of phospholipase D in M-dependent rodent cortical plasticity. Moran SP, Xiang Z, Doyle CA, Maksymetz J, Lv X, Faltin S, Fisher NM, Niswender CM, Rook JM, Lindsley CW, Conn PJ (2019) Sci Signal 12(610)
    › Primary publication · 31796631 (PubMed) · PMC6936752 (PubMed Central)
  2. VU6007477, a Novel M PAM Based on a Pyrrolo[2,3-]pyridine Carboxamide Core Devoid of Cholinergic Adverse Events. Engers JL, Childress ES, Long MF, Capstick RA, Luscombe VB, Cho HP, Dickerson JW, Rook JM, Blobaum AL, Niswender CM, Engers DW, Conn PJ, Lindsley CW (2018) ACS Med Chem Lett 9(9): 917-922
    › Primary publication · 30258541 (PubMed) · PMC6142057 (PubMed Central)
  3. Discovery of Tricyclic Triazolo- and Imidazopyridine Lactams as M Positive Allosteric Modulators. Engers JL, Bender AM, Kalbfleisch JJ, Cho HP, Lingenfelter KS, Luscombe VB, Han C, Melancon BJ, Blobaum AL, Dickerson JW, Rook JM, Niswender CM, Emmitte KA, Conn PJ, Lindsley CW (2019) ACS Chem Neurosci 10(3): 1035-1042
    › Primary publication · 30086237 (PubMed) · PMC6456254 (PubMed Central)
  4. Mutual activation of glutamatergic mGlu and muscarinic M receptors reverses schizophrenia-related changes in rodents. Cieślik P, Woźniak M, Rook JM, Tantawy MN, Conn PJ, Acher F, Tokarski K, Kusek M, Pilc A, Wierońska JM (2018) Psychopharmacology (Berl) 235(10): 2897-2913
    › Primary publication · 30054675 (PubMed) · PMC6182605 (PubMed Central)
  5. The discovery of VU0486846: steep SAR from a series of M PAMs based on a novel benzomorpholine core. Bertron JL, Cho HP, Garcia-Barrantes PM, Panarese JD, Salovich JM, Nance KD, Engers DW, Rook JM, Blobaum AL, Niswender CM, Stauffer SR, Conn PJ, Lindsley CW (2018) Bioorg Med Chem Lett 28(12): 2175-2179
    › Primary publication · 29754948 (PubMed) · PMC6427922 (PubMed Central)
  6. PF-06827443 Displays Robust Allosteric Agonist and Positive Allosteric Modulator Activity in High Receptor Reserve and Native Systems. Moran SP, Cho HP, Maksymetz J, Remke DH, Hanson RM, Niswender CM, Lindsley CW, Rook JM, Conn PJ (2018) ACS Chem Neurosci 9(9): 2218-2224
    › Primary publication · 29683646 (PubMed) · PMC6146053 (PubMed Central)
  7. mGlu and mGlu modulate distinct excitatory inputs to the nucleus accumbens shell. Turner BD, Rook JM, Lindsley CW, Conn PJ, Grueter BA (2018) Neuropsychopharmacology 43(10): 2075-2082
    › Primary publication · 29654259 (PubMed) · PMC6097986 (PubMed Central)
  8. M-positive allosteric modulators lacking agonist activity provide the optimal profile for enhancing cognition. Moran SP, Dickerson JW, Cho HP, Xiang Z, Maksymetz J, Remke DH, Lv X, Doyle CA, Rajan DH, Niswender CM, Engers DW, Lindsley CW, Rook JM, Conn PJ (2018) Neuropsychopharmacology 43(8): 1763-1771
    › Primary publication · 29581537 (PubMed) · PMC6006294 (PubMed Central)
  9. Cholinergic Projections to the Substantia Nigra Pars Reticulata Inhibit Dopamine Modulation of Basal Ganglia through the M Muscarinic Receptor. Moehle MS, Pancani T, Byun N, Yohn SE, Wilson GH, Dickerson JW, Remke DH, Xiang Z, Niswender CM, Wess J, Jones CK, Lindsley CW, Rook JM, Conn PJ (2017) Neuron 96(6): 1358-1372.e4
    › Primary publication · 29268098 (PubMed) · PMC5753765 (PubMed Central)
  10. VU6010608, a Novel mGlu NAM from a Series of -(2-(1-1,2,4-Triazol-1-yl)-5-(trifluoromethoxy)phenyl)benzamides. Reed CW, McGowan KM, Spearing PK, Stansley BJ, Roenfanz HF, Engers DW, Rodriguez AL, Engelberg EM, Luscombe VB, Loch MT, Remke DH, Rook JM, Blobaum AL, Conn PJ, Niswender CM, Lindsley CW (2017) ACS Med Chem Lett 8(12): 1326-1330
    › Primary publication · 29259756 (PubMed) · PMC5733308 (PubMed Central)
  11. Role of mGlu Receptors and Inhibitory Neurotransmission in M Dependent Muscarinic LTD in the Prefrontal Cortex: Implications in Schizophrenia. Ghoshal A, Moran SP, Dickerson JW, Joffe ME, Grueter BA, Xiang Z, Lindsley CW, Rook JM, Conn PJ (2017) ACS Chem Neurosci 8(10): 2254-2265
    › Primary publication · 28679049 (PubMed) · PMC5791524 (PubMed Central)
  12. Co-Activation of Metabotropic Glutamate Receptor 3 and Beta-Adrenergic Receptors Modulates Cyclic-AMP and Long-Term Potentiation, and Disrupts Memory Reconsolidation. Walker AG, Sheffler DJ, Lewis AS, Dickerson JW, Foster DJ, Senter RK, Moehle MS, Lv X, Stansley BJ, Xiang Z, Rook JM, Emmitte KA, Lindsley CW, Conn PJ (2017) Neuropsychopharmacology 42(13): 2553-2566
    › Primary publication · 28664928 (PubMed) · PMC5686489 (PubMed Central)
  13. Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation. Felts AS, Rodriguez AL, Blobaum AL, Morrison RD, Bates BS, Thompson Gray A, Rook JM, Tantawy MN, Byers FW, Chang S, Venable DF, Luscombe VB, Tamagnan GD, Niswender CM, Daniels JS, Jones CK, Conn PJ, Lindsley CW, Emmitte KA (2017) J Med Chem 60(12): 5072-5085
    › Primary publication · 28530802 (PubMed) · PMC5484149 (PubMed Central)
  14. M muscarinic activation induces long-lasting increase in intrinsic excitability of striatal projection neurons. Lv X, Dickerson JW, Rook JM, Lindsley CW, Conn PJ, Xiang Z (2017) Neuropharmacology : 209-222
    › Primary publication · 28336323 (PubMed) · PMC5501169 (PubMed Central)
  15. Diverse Effects on M Signaling and Adverse Effect Liability within a Series of M Ago-PAMs. Rook JM, Abe M, Cho HP, Nance KD, Luscombe VB, Adams JJ, Dickerson JW, Remke DH, Garcia-Barrantes PM, Engers DW, Engers JL, Chang S, Foster JJ, Blobaum AL, Niswender CM, Jones CK, Conn PJ, Lindsley CW (2017) ACS Chem Neurosci 8(4): 866-883
    › Primary publication · 28001356 (PubMed) · PMC5460155 (PubMed Central)
  16. Antipsychotic-like Effects of M4 Positive Allosteric Modulators Are Mediated by CB2 Receptor-Dependent Inhibition of Dopamine Release. Foster DJ, Wilson JM, Remke DH, Mahmood MS, Uddin MJ, Wess J, Patel S, Marnett LJ, Niswender CM, Jones CK, Xiang Z, Lindsley CW, Rook JM, Conn PJ (2016) Neuron 91(6): 1244-1252
    › Primary publication · 27618677 (PubMed) · PMC5033724 (PubMed Central)
  17. Optimization of the choline transporter (CHT) inhibitor ML352: Development of VU6001221, an improved in vivo tool compound. Bertron JL, Ennis EA, Tarr CJ, Wright J, Dickerson JW, Locuson CW, Blobaum AL, Rook JM, Blakely RD, Lindsley CW (2016) Bioorg Med Chem Lett 26(19): 4637-4640
    › Primary publication · 27575469 (PubMed)
  18. mGlu5 positive allosteric modulation normalizes synaptic plasticity defects and motor phenotypes in a mouse model of Rett syndrome. Gogliotti RG, Senter RK, Rook JM, Ghoshal A, Zamorano R, Malosh C, Stauffer SR, Bridges TM, Bartolome JM, Daniels JS, Jones CK, Lindsley CW, Conn PJ, Niswender CM (2016) Hum Mol Genet 25(10): 1990-2004
    › Primary publication · 26936821 (PubMed) · PMC5062588 (PubMed Central)
  19. An mGlu5-Positive Allosteric Modulator Rescues the Neuroplasticity Deficits in a Genetic Model of NMDA Receptor Hypofunction in Schizophrenia. Balu DT, Li Y, Takagi S, Presti KT, Ramikie TS, Rook JM, Jones CK, Lindsley CW, Conn PJ, Bolshakov VY, Coyle JT (2016) Neuropsychopharmacology 41(8): 2052-61
    › Primary publication · 26741285 (PubMed) · PMC4908650 (PubMed Central)
  20. Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice. Pancani T, Foster DJ, Moehle MS, Bichell TJ, Bradley E, Bridges TM, Klar R, Poslusney M, Rook JM, Daniels JS, Niswender CM, Jones CK, Wood MR, Bowman AB, Lindsley CW, Xiang Z, Conn PJ (2015) Proc Natl Acad Sci U S A 112(45): 14078-83
    › Primary publication · 26508634 (PubMed) · PMC4653197 (PubMed Central)
  21. Acyl dihydropyrazolo[1,5-a]pyrimidinones as metabotropic glutamate receptor 5 positive allosteric modulators. Malosh C, Turlington M, Bridges TM, Rook JM, Noetzel MJ, Vinson PN, Steckler T, Lavreysen H, Mackie C, Bartolomé-Nebreda JM, Conde-Ceide S, Martínez-Viturro CM, Piedrafita M, Sánchez-Casado MR, Macdonald GJ, Daniels JS, Jones CK, Niswender CM, Conn PJ, Lindsley CW, Stauffer SR (2015) Bioorg Med Chem Lett 25(22): 5115-20
    › Primary publication · 26475522 (PubMed) · PMC4634704 (PubMed Central)
  22. Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu1), Based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild Type and Mutant mGlu1 Receptors Found in Schizophrenics. Garcia-Barrantes PM, Cho HP, Niswender CM, Byers FW, Locuson CW, Blobaum AL, Xiang Z, Rook JM, Conn PJ, Lindsley CW (2015) J Med Chem 58(20): 7959-71
    › Primary publication · 26426481 (PubMed) · PMC4839290 (PubMed Central)
  23. Partial mGlu₅ Negative Allosteric Modulators Attenuate Cocaine-Mediated Behaviors and Lack Psychotomimetic-Like Effects. Gould RW, Amato RJ, Bubser M, Joffe ME, Nedelcovych MT, Thompson AD, Nickols HH, Yuh JP, Zhan X, Felts AS, Rodriguez AL, Morrison RD, Byers FW, Rook JM, Daniels JS, Niswender CM, Conn PJ, Emmitte KA, Lindsley CW, Jones CK (2016) Neuropsychopharmacology 41(4): 1166-78
    › Primary publication · 26315507 (PubMed) · PMC4748441 (PubMed Central)
  24. Discovery of VU0409551/JNJ-46778212: An mGlu5 Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia. Conde-Ceide S, Martínez-Viturro CM, Alcázar J, Garcia-Barrantes PM, Lavreysen H, Mackie C, Vinson PN, Rook JM, Bridges TM, Daniels JS, Megens A, Langlois X, Drinkenburg WH, Ahnaou A, Niswender CM, Jones CK, Macdonald GJ, Steckler T, Conn PJ, Stauffer SR, Bartolomé-Nebreda JM, Lindsley CW (2015) ACS Med Chem Lett 6(6): 716-20
    › Primary publication · 26157544 (PubMed) · PMC4492464 (PubMed Central)
  25. Potentiation of M1 Muscarinic Receptor Reverses Plasticity Deficits and Negative and Cognitive Symptoms in a Schizophrenia Mouse Model. Ghoshal A, Rook JM, Dickerson JW, Roop GN, Morrison RD, Jalan-Sakrikar N, Lamsal A, Noetzel MJ, Poslusney MS, Wood MR, Melancon BJ, Stauffer SR, Xiang Z, Daniels JS, Niswender CM, Jones CK, Lindsley CW, Conn PJ (2016) Neuropsychopharmacology 41(2): 598-610
    › Primary publication · 26108886 (PubMed) · PMC5130135 (PubMed Central)
  26. Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR Currents. Rook JM, Xiang Z, Lv X, Ghoshal A, Dickerson JW, Bridges TM, Johnson KA, Foster DJ, Gregory KJ, Vinson PN, Thompson AD, Byun N, Collier RL, Bubser M, Nedelcovych MT, Gould RW, Stauffer SR, Daniels JS, Niswender CM, Lavreysen H, Mackie C, Conde-Ceide S, Alcazar J, Bartolomé-Nebreda JM, Macdonald GJ, Talpos JC, Steckler T, Jones CK, Lindsley CW, Conn PJ (2015) Neuron 86(4): 1029-1040
    › Primary publication · 25937172 (PubMed) · PMC4443790 (PubMed Central)
  27. Effects of VU0410120, a novel GlyT1 inhibitor, on measures of sociability, cognition and stereotypic behaviors in a mouse model of autism. Burket JA, Benson AD, Green TL, Rook JM, Lindsley CW, Conn PJ, Deutsch SI (2015) Prog Neuropsychopharmacol Biol Psychiatry : 10-7
    › Primary publication · 25784602 (PubMed)
  28. Metabotropic glutamate receptor 3 activation is required for long-term depression in medial prefrontal cortex and fear extinction. Walker AG, Wenthur CJ, Xiang Z, Rook JM, Emmitte KA, Niswender CM, Lindsley CW, Conn PJ (2015) Proc Natl Acad Sci U S A 112(4): 1196-201
    › Primary publication · 25583490 (PubMed) · PMC4313856 (PubMed Central)
  29. Relationship between in vivo receptor occupancy and efficacy of metabotropic glutamate receptor subtype 5 allosteric modulators with different in vitro binding profiles. Rook JM, Tantawy MN, Ansari MS, Felts AS, Stauffer SR, Emmitte KA, Kessler RM, Niswender CM, Daniels JS, Jones CK, Lindsley CW, Conn PJ (2015) Neuropsychopharmacology 40(3): 755-65
    › Primary publication · 25241804 (PubMed) · PMC4289965 (PubMed Central)
  30. Identification of specific ligand-receptor interactions that govern binding and cooperativity of diverse modulators to a common metabotropic glutamate receptor 5 allosteric site. Gregory KJ, Nguyen ED, Malosh C, Mendenhall JL, Zic JZ, Bates BS, Noetzel MJ, Squire EF, Turner EM, Rook JM, Emmitte KA, Stauffer SR, Lindsley CW, Meiler J, Conn PJ (2014) ACS Chem Neurosci 5(4): 282-95
    › Primary publication · 24528109 (PubMed) · PMC3990945 (PubMed Central)
  31. Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer's disease and schizophrenia. Foster DJ, Choi DL, Conn PJ, Rook JM (2014) Neuropsychiatr Dis Treat : 183-91
    › Primary publication · 24511233 (PubMed) · PMC3913542 (PubMed Central)
  32. Exploration of allosteric agonism structure-activity relationships within an acetylene series of metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs): discovery of 5-((3-fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinamide (ML254). Turlington M, Noetzel MJ, Chun A, Zhou Y, Gogliotti RD, Nguyen ED, Gregory KJ, Vinson PN, Rook JM, Gogi KK, Xiang Z, Bridges TM, Daniels JS, Jones C, Niswender CM, Meiler J, Conn PJ, Lindsley CW, Stauffer SR (2013) J Med Chem 56(20): 7976-96
    › Primary publication · 24050755 (PubMed) · PMC3908770 (PubMed Central)
  33. Biotransformation of a novel positive allosteric modulator of metabotropic glutamate receptor subtype 5 contributes to seizure-like adverse events in rats involving a receptor agonism-dependent mechanism. Bridges TM, Rook JM, Noetzel MJ, Morrison RD, Zhou Y, Gogliotti RD, Vinson PN, Xiang Z, Jones CK, Niswender CM, Lindsley CW, Stauffer SR, Conn PJ, Daniels JS (2013) Drug Metab Dispos 41(9): 1703-14
    › Primary publication · 23821185 (PubMed) · PMC3876804 (PubMed Central)
  34. Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activity. Rook JM, Noetzel MJ, Pouliot WA, Bridges TM, Vinson PN, Cho HP, Zhou Y, Gogliotti RD, Manka JT, Gregory KJ, Stauffer SR, Dudek FE, Xiang Z, Niswender CM, Daniels JS, Jones CK, Lindsley CW, Conn PJ (2013) Biol Psychiatry 73(6): 501-9
    › Primary publication · 23140665 (PubMed) · PMC3572342 (PubMed Central)
  35. Investigating metabotropic glutamate receptor 5 allosteric modulator cooperativity, affinity, and agonism: enriching structure-function studies and structure-activity relationships. Gregory KJ, Noetzel MJ, Rook JM, Vinson PN, Stauffer SR, Rodriguez AL, Emmitte KA, Zhou Y, Chun AC, Felts AS, Chauder BA, Lindsley CW, Niswender CM, Conn PJ (2012) Mol Pharmacol 82(5): 860-75
    › Primary publication · 22863693 (PubMed) · PMC3477233 (PubMed Central)
  36. Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function. Noetzel MJ, Rook JM, Vinson PN, Cho HP, Days E, Zhou Y, Rodriguez AL, Lavreysen H, Stauffer SR, Niswender CM, Xiang Z, Daniels JS, Jones CK, Lindsley CW, Weaver CD, Conn PJ (2012) Mol Pharmacol 81(2): 120-33
    › Primary publication · 22021324 (PubMed) · PMC3263948 (PubMed Central)
  37. Allosteric modulation of metabotropic glutamate receptors. Sheffler DJ, Gregory KJ, Rook JM, Conn PJ (2011) Adv Pharmacol : 37-77
    › Primary publication · 21907906 (PubMed) · PMC3787868 (PubMed Central)
  38. Impact of isoflurane anesthesia on D2 receptor occupancy by [18F]fallypride measured by microPET with a modified Logan plot. Tantawy MN, Peterson TE, Jones CK, Johnson K, Rook JM, Conn PJ, Baldwin RM, Ansari MS, Kessler RM (2011) Synapse 65(11): 1173-80
    › Primary publication · 21584868 (PubMed) · PMC4078917 (PubMed Central)
  39. Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Rodriguez AL, Grier MD, Jones CK, Herman EJ, Kane AS, Smith RL, Williams R, Zhou Y, Marlo JE, Days EL, Blatt TN, Jadhav S, Menon UN, Vinson PN, Rook JM, Stauffer SR, Niswender CM, Lindsley CW, Weaver CD, Conn PJ (2010) Mol Pharmacol 78(6): 1105-23
    › Primary publication · 20923853 (PubMed) · PMC2993468 (PubMed Central)
  40. Discovery of molecular switches that modulate modes of metabotropic glutamate receptor subtype 5 (mGlu5) pharmacology in vitro and in vivo within a series of functionalized, regioisomeric 2- and 5-(phenylethynyl)pyrimidines. Sharma S, Kedrowski J, Rook JM, Smith RL, Jones CK, Rodriguez AL, Conn PJ, Lindsley CW (2009) J Med Chem 52(14): 4103-6
    › Primary publication · 19537763 (PubMed) · PMC3192011 (PubMed Central)